These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 14508385

  • 1. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
    Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J.
    Ther Drug Monit; 2003 Oct; 25(5):609-22. PubMed ID: 14508385
    [Abstract] [Full Text] [Related]

  • 2. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil.
    Morissette P, Albert C, Busque S, St-Louis G, Vinet B.
    Ther Drug Monit; 2001 Oct; 23(5):520-5. PubMed ID: 11591897
    [Abstract] [Full Text] [Related]

  • 3. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
    [Abstract] [Full Text] [Related]

  • 4. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

  • 5. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
    Naito T, Shinno K, Maeda T, Kagawa Y, Hashimoto H, Otsuka A, Takayama T, Ushiyama T, Suzuki K, Ozono S.
    Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [Abstract] [Full Text] [Related]

  • 8. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.
    Clin Pharmacokinet; 2009 Dec; 48(11):745-58. PubMed ID: 19817503
    [Abstract] [Full Text] [Related]

  • 9. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 10. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M.
    Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation.
    Sobiak J, Resztak M, Głyda M, Szczepaniak P, Chrzanowska M.
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):331-8. PubMed ID: 25663618
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, Zimmerhackl LB, Schütz E, Mehls O, Oellerich M, Armstrong VW, Tönshoff B.
    J Am Soc Nephrol; 1998 Aug; 9(8):1511-20. PubMed ID: 9697675
    [Abstract] [Full Text] [Related]

  • 13. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis.
    Morgera S, Neumayer HH, Fritsche L, Kuchinke S, Lampe D, Ahnert V, Bauer S, Mai I, Budde K.
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):159-63. PubMed ID: 9562232
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [Abstract] [Full Text] [Related]

  • 16. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J.
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [Abstract] [Full Text] [Related]

  • 17. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
    Jain AB, Hamad I, Zuckerman S, Zhang S, Warty VS, Fung JJ, Venkataramanan R.
    Liver Transpl Surg; 1999 Mar; 5(2):101-6. PubMed ID: 10071348
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.
    Clin Chem; 2001 Mar; 47(7):1241-8. PubMed ID: 11427455
    [Abstract] [Full Text] [Related]

  • 19. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide.
    Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR.
    Transplantation; 2007 Aug 15; 84(3):362-73. PubMed ID: 17700162
    [Abstract] [Full Text] [Related]

  • 20. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE, Nicholls AJ, Kamm BR.
    Clin Pharmacokinet; 1998 Jun 15; 34(6):429-55. PubMed ID: 9646007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.